- Home
- WRBY vs KROS Comparison
WRBY vs KROS Comparison
Compare WRBY & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRBY
- KROS
- Stock Information
- Founded
- WRBY 2010
- KROS 2015
- Country
- WRBY United States
- KROS United States
- Employees
- WRBY N/A
- KROS N/A
- Industry
- WRBY Ophthalmic Goods
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- WRBY Health Care
- KROS Health Care
- Exchange
- WRBY Nasdaq
- KROS Nasdaq
- Market Cap
- WRBY 2.1B
- KROS 558.9M
- IPO Year
- WRBY 2021
- KROS 2020
- Fundamental
- Price
- WRBY $21.84
- KROS $13.37
- Analyst Decision
- WRBY Buy
- KROS Buy
- Analyst Count
- WRBY 15
- KROS 13
- Target Price
- WRBY $23.33
- KROS $20.63
- AVG Volume (30 Days)
- WRBY 2.0M
- KROS 637.6K
- Earning Date
- WRBY 08-07-2025
- KROS 08-06-2025
- Dividend Yield
- WRBY N/A
- KROS N/A
- EPS Growth
- WRBY N/A
- KROS N/A
- EPS
- WRBY N/A
- KROS 0.11
- Revenue
- WRBY $795,094,000.00
- KROS $214,713,000.00
- Revenue This Year
- WRBY $16.13
- KROS $5,006.76
- Revenue Next Year
- WRBY $13.87
- KROS N/A
- P/E Ratio
- WRBY N/A
- KROS $123.16
- Revenue Growth
- WRBY 13.94
- KROS 91657.70
- 52 Week Low
- WRBY $12.46
- KROS $9.12
- 52 Week High
- WRBY $28.68
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- WRBY 60.65
- KROS 42.27
- Support Level
- WRBY $20.85
- KROS $13.25
- Resistance Level
- WRBY $22.46
- KROS $13.99
- Average True Range (ATR)
- WRBY 0.79
- KROS 0.36
- MACD
- WRBY -0.14
- KROS -0.06
- Stochastic Oscillator
- WRBY 51.56
- KROS 20.75
About WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.